Kanter Stacy J. 4

What Happened

• Stacy J. Kanter, a director of Applied Therapeutics (APLT), reported dispositions totaling 328,690 shares on 2026-02-03. The shares were cancelled/converted pursuant to the company's merger agreement; the filing reports the transactions as dispositions to the issuer and in connection with a change of control.
• Under the Merger Agreement, each cancelled share converted into $0.088 in cash (net per share) plus one non‑tradeable contingent value right (CVR). The cash component for 328,690 shares is about $28,924.72; holders also receive the CVR per the agreement. Several of the reported dispositions relate to derivative awards (RSUs and options) that were deemed vested and converted or cancelled in the merger.

Key Details

• Transaction date(s): Reported dispositions dated 2026-02-03; Merger effective time per footnote: 2026-01-28.
• Price/consideration: $0.088 cash per common share plus one non-tradeable contingent value right (filing shows N/A for per-line price).
• Shares disposed: 22,500; 42,500; 20,460; 10,230; 16,500; 16,500; and 200,000 — total 328,690 shares.
• Derivative items: RSUs (vested and converted into merger consideration) and certain stock options were vested or cancelled per the Merger Agreement (out‑of‑the‑money options cancelled for no consideration).
• Shares owned after transaction: not specified in the filing.
• Filing date: Form 4 filed 2026-02-04. The filing does not state that it was late.

Context

• These dispositions were driven by a corporate merger/tender offer, not open‑market selling. Cancellation/conversion of common shares, RSUs and certain options into the merger consideration is common in change‑of‑control transactions and does not necessarily reflect personal trading intent.
• The cash received is modest (~$28.9K); holders also received CVRs, which may have future contingent value depending on the agreement terms.